# Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

> **NCT04056611** · PHASE2 · TERMINATED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 3 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** JNJ-53718678 250 mg
- **DRUG:** Placebo
- **DRUG:** JNJ-53718678 125 mg

## Key facts

- **NCT ID:** NCT04056611
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-26
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** A strategic decision was made to discontinue the study. The decision was not based on a safety concern.
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056611, "Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04056611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*